Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • January 2018
  • Article
  • JAMA Cardiology

The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials

By: Aaron V. Kaplan and Ariel Dora Stern
  • Format:Print
ShareBar

Abstract

The introduction of new medical devices has transformed cardiovascular care in recent decades. Devices, such as heart valves, pacemakers, stents, ventricular assist devices, and implantable defibrillators, have prolonged and improved the quality of life for millions of patients worldwide. Medical device innovation requires a robust ecosystem that involves medical technology innovators, often at start-ups, large medical device manufacturers, and clinical investigators. Central to this process is strong regulatory oversight, which in the United States is provided by the U.S. Food and Drug Administration’s Center for Devices and Radiologic Health (FDA/CDRH). This viewpoint discusses the effect of the regulatory approval process and the role that FDA/CDRH plays in the design and execution of the pivotal trials (clinical studies) that are used to support the regulatory approval of high-risk devices. We also review norms in the publication of pivotal trials in peer-reviewed medical journals; these publications often fail to acknowledge the role of the FDA/CRH or discuss results within the context of the device approval process.

Keywords

Health Testing and Trials; Business and Government Relations; Governing Rules, Regulations, and Reforms; Information Publishing; Medical Devices and Supplies Industry; United States

Citation

Kaplan, Aaron V., and Ariel Dora Stern. "The Central and Unacknowledged Role of the U.S. Food and Drug Administration in the Design and Execution of Medical Device Pivotal Trials." JAMA Cardiology 3, no. 1 (January 2018): 5–6.
  • Find it at Harvard

About The Author

Ariel D. Stern

Technology and Operations Management
→More Publications

More from the Authors

    • Harvard Business Manager

    Ein Booster für die Pharmabranche: Gerade erst hat die mRNATechnologie geholfen, Impfstoffe gegen Covid-19 zu entwickeln. Nun könnte sie wie Apples iOS die Grundlage für neue Innovationsplattformen bieten.

    By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
    • April 18, 2022
    • Harvard Business Review (website)

    Will mRNA Technology Companies Spawn Innovation Ecosystems?

    By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
    • April 2022
    • NEJM Catalyst Innovations in Care Delivery

    AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care

    By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
More from the Authors
  • Ein Booster für die Pharmabranche: Gerade erst hat die mRNATechnologie geholfen, Impfstoffe gegen Covid-19 zu entwickeln. Nun könnte sie wie Apples iOS die Grundlage für neue Innovationsplattformen bieten. By: Ariel Dora Stern, Timo Minssen, W. Nicholson Price, II and Christoph Grimpe
  • Will mRNA Technology Companies Spawn Innovation Ecosystems? By: Christoph Grimpe, Timo Minssen, W. Nicholson Price, II and Ariel Dora Stern
  • AI Insurance: How Liability Insurance Can Drive the Responsible Adoption of Artificial Intelligence in Health Care By: Ariel Dora Stern, Avi Goldfarb and Timo Minssen
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College